Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Depressive Disorder, Major

In brief

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).

Key facts

Study ID
NCT03614156
Run by
Naurex, Inc, an affiliate of Allergan plc
People needed
363
Starts
2018-08-02
Expected to finish
2019-07-11
Last updated by the study team
2020-10-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.